BDA advises Khandelwal Labs on sale of non-oncology branded generics business to Aurobindo

BDA Partners is pleased to announce that its client, Khandelwal Laboratories Pvt Ltd (“KLAB”), has sold its branded generic non-oncology prescription formulations business to Auro Pharma Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd.

KLAB’s non-oncology business includes a portfolio of branded generic products across key therapeutic areas, including pain management, gastrointestinal, and anti-infective treatments. The business has established a strong market presence in India through its established product line and dedicated marketing team.

BDA acted as exclusive financial advisor to KLAB on the transaction, which was executed on a slump sale basis under a Business Transfer Agreement.

The acquisition allows Auro Pharma to expand its domestic formulation business in India, adding established brands in critical therapeutic areas. This will complement Aurobindo’s existing product portfolio and leverage its scale as a leader in the pharma sector.

S. K. Pai Kakode, Director, KLAB, said: “We are pleased to divest the non-oncology prescription formulation business division to Auro Pharma Limited. The acquisition will support Auro Pharma’s growth plans in the domestic branded formulation business segment. The BDA team played a pivotal role in this transaction, using its sector expertise and strategic investor access to find the optimal partner for next phase of growth.”

Aditya Jaju, Director, BDA Partners, said: “We are pleased to have advised KLAB on this strategic divestment. The BDA team used sector knowledge and deep relationships within the Indian pharma landscape to achieve a simultaneous sign & close. The transaction strengthens BDA’s credentials in the life sciences value chain.”

Andrew Huntley, Managing Partner, Head of Healthcare, BDA Partners, said: “We’re delighted to have helped KLAB achieve this result, and congratulate Auro Pharma on the acquisition. Our Healthcare team in India continues to deploy global and local knowledge in the pharma and health spaces for the benefit of our clients.”